NLRP3 and primary cutaneous T-cell non-Hodgkin lymphoma: These results support the ability of IL-4 to inhibit NLRP3 inflammasome assembly, thereby promoting nuclear localization of this receptor in CTCL lesions and possibly contributing to disease progression since tumor lesions show augmented NLRP3 expression in TOX+ T cells.